> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Positive Results for Roche Giredestrant in Some Breast Cancers
- URL: https://www.fdaweb.com/positive-results-for-roche-giredestrant-in-some-breast-cancers/
- Published: 2025-12-10T12:00:00.000Z
- Updated: 2026-09-14T15:28:51.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5160360

Roche says results from the Phase 3 lidERA breast cancer study evaluating its investigational giredestrant as adjuvant endocrine treatment for people with estrogen receptor-positive, human epidermal growth factor receptor 2-negative early-stage breast cancer showed the treatment significantly reduced the risk of invasive disease recurrence or death by 30% compared with standard-of-care endocrine therapy. A Roche [announcement](https://www.roche.com/media/releases/med-cor-2025-12-10?ref=fdaweb.com) says giredestrant is the only selective estrogen receptor degrader to show superior disease-free survival in the adjuvant setting, marking the first significant endocrine therapy advance in over 20 years.

“The transformational results support the potential of giredestrant to become a new standard-of-care for early-stage disease,” the company says.

Roche says giredestrant is designed to block estrogen from binding to the estrogen receptor, triggering degradation and stopping or slowing the growth of cancer cells.